- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.11. | Merck writes tale of 2 checks, bagging $700M from Blackstone and spending $150M to regain asset | ||
| 04.11. | Nuvation cancels plans to test brain cancer drug directly against Voranigo on FDA's advice | ||
| 04.11. | Celltrion looks beyond biosimilars with $744M pact for 2 preclinical autoimmune drugs | ||
| 03.11. | Tempero calls time on alcohol use disorder while mulling options, according to partner | ||
| 03.11. | uniQure's ballyhooed gene therapy for Huntington's hits FDA roadblock | ||
| 03.11. | Roche signs $2B pact to pilot Manifold Bio's shuttles to the brain | ||
| 03.11. | TScan lays off 30% of workforce, halts phase 1 solid tumor T-cell receptor trial | ||
| 03.11. | Neurocrine pens $880M deal with China's TransThera for red-hot immunology target | ||
| 03.11. | Pfizer sues Metsera over Novo's shock counter-offer, but obesity biotech stands firm | ||
| 31.10. | Biotech Graveyard | ||
| 31.10. | Cash-strapped Nanobiotix finds fresh way to source cash from J&J-partnered cancer drug | ||
| 31.10. | 4DMT eyes $420M deal from Otsuka, with cash aimed at retinal gene therapy's phase 3 plans | ||
| 30.10. | Eli Lilly sidelines midstage prospect in another pain pipeline pivot | ||
| 30.10. | BMS culls 2 clinical programs, one from Mirati and another from Exscientia | ||
| 30.10. | Inflammation biotech Evommune prices IPO after MapLight's $250M debut | ||
| 30.10. | Sensei drops sole clinical-stage cancer drug, plans layoffs to conserve remaining cash | ||
| 30.10. | Takeda drops AstraZeneca-partnered neurological program after phase 2 failure | ||
| 30.10. | Novo makes bombshell $6.5B counteroffer to Pfizer's acquisition of obesity biotech Metsera | ||
| 30.10. | FDA places Intellia phase 3 CRISPR trials on hold over raised liver enzymes | ||
| 30.10. | Boehringer returns to Kyowa Kirin with €640M pact for preclinical autoimmune molecule | ||
| 30.10. | Roche pens $1B biobucks deal for Chinese company's respiratory disease bispecific | ||
| 29.10. | Genentech says goodbye to 118 employees in third HQ layoff round of the year | ||
| 29.10. | AbbVie halts development of Dragonfly cancer asset midflight | ||
| 29.10. | Novartis drug reduces Sjögren's activity, patient burden in late-stage trials despite notable placebo effect | ||
| 29.10. | Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .